Table 1.
Nanomaterial-carrying drugs in clinical trials of cancer treatment in the past five years.
| Year | Drugs | Disease | Findings | Reference | |
|---|---|---|---|---|---|
| Liposome | 2015 | Doxorubicin | Platinum-Sensitive Ovarian Cancer | favorable risk-benefit profile | 97 |
| Paclitaxel | Non-Small Cell Lung Cancer | considerable disease response and resection rate, with acceptable toxicity | 98 | ||
| Ursolic acid | Advanced Solid Tumors | tolerable, manageable toxicity, improving patient remission rates | 99 | ||
| Mitomycin C | advanced cancer | long circulation time, tolerable, effective | 100 | ||
| 2016 | miR-34a Mimic | Advanced Solid Tumors | effective | 101 | |
| Vincristine Sulfate | Refractory Solid Tumors or Leukemias | without dose-limiting neurotoxicity | 102 | ||
| 5-fluorouracil and Leucovorin | Advanced Solid Tumors | lower peak plasma concentration, longer half-life, and increased area | 103 | ||
| Cytarabine | Childhood Acute Lymphoblastic Leukemia | no permanent adverse neurological sequelae | 104 | ||
| 2017 | Amphotericin | Acute Lymphoblastic Leukaemia | effective | 105 | |
| Irinotecan | Recurrent High-Grade Glioma | no unexpected toxicities | 106 | ||
| 2018 | Cytarabine and Daunorubicin | Newly Diagnosed Secondary Acute Myeloid Leukemia | significantly longer survival rate | 107 | |
| Curcumin | Locally Advanced or Metastatic Cancer | durable | 108 | ||
| Daunorubicin | Pediatric Relapsed/Refractory Acute Myeloid Leukemia | well-tolerated and showed high response rates | 109 | ||
| Lipovaxin-MM | Malignant Melanoma | well-tolerated and without clinically significant toxicity | 110 | ||
| Vincristine Sulfate | Acute Lymphoblastic Leukemia | provided a meaningful clinical benefit and safety | 111 | ||
| Oligodeoxynucleotide | Refractory or Relapsed Haematological Malignancies | well-tolerated, effective | 112 | ||
| 2019 | Eribulin | Solid Tumours | well-tolerated with a favorable pharmacokinetic profile | 113 | |
| Polymeric Micelles | 2017 | Epirubicin | Solid tumors | Well tolerated in patients with various solid tumors and exhibited less toxicity than conventional epirubicin formulations | 114 |
| 2018 | Genexol-PM plus carboplatin | Ovarian Cancer | Non-inferior efficacy and well-tolerated toxicities | 115 | |
| 2019 | Paclitaxel (PTX) | Breast cancer | NK105 had a better PSN toxicity profile than PTX | 116 |